Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation

LESSONS LEARNED: Cediranib and olaparib combination did not result in clinically meaningful activity in patients with metastatic pancreatic ductal adenocarcinoma without known BRCA mutation. BACKGROUND: Cediranib, a vascular endothelial growth factor receptor inhibitor, suppresses expression of BRCA...

全面介紹

Na minha lista:
書目詳細資料
發表在:Oncologist
Main Authors: Kim, Joseph W., Cardin, Dana B., Vaishampayan, Ulka N., Kato, Shumei, Grossman, Steven R., Glazer, Peter M., Shyr, Yu, Ivy, S. Percy, LoRusso, Patricia M.
格式: Artigo
語言:Inglês
出版: John Wiley & Sons, Inc. 2021
主題:
Clinical Trial Results
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC8265343/
https://ncbi.nlm.nih.gov/pubmed/33742489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13758
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍